Drugs Made In America Acquisition (DMIIR) Payables (2024 - 2025)

Drugs Made In America Acquisition's (DMIIR) quarterly Payables came in at $99359.0 in Q4 2025, down 60.27% year-on-year from $250100.0 in Q4 2024, and up 2063.74% on a QoQ basis from $4592.0 in Q3 2025.

Drugs Made In America Acquisition (DMIIR) Payables (2024 - 2025) Analysis & Trends

Drugs Made In America Acquisition (DMIIR) has 2 years of Payables data on file, last reported at $99359.0 in Q4 2025.

  • On a quarterly basis, Payables fell 60.27% year-over-year to $99359.0 in Q4 2025; TTM through Dec 2025 was $99359.0, a 60.27% decrease from a year earlier, with the FY2025 full-year figure at $99359.0, down 60.27% from the prior year.
  • Payables for Q4 2025 stood at $99359.0, up from $4592.0 in the prior quarter.
  • Over the last five years, Payables for DMIIR reached as high as $250100.0 in Q4 2024 and fell as low as $4592.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Payables (Qtr)
1 EQV Ventures Acquisition 480.75 Mn 480.75 Mn - -
2 Agriculture & Natural Solutions Acquisition 393.29 Mn 393.29 Mn - 2.87 Mn
3 Berto Acquisition 314.56 Mn 314.35 Mn - 240,058.00
4 GP-Act III Acquisition 313.66 Mn 313.66 Mn - 200,000.00
5 Centurion Acquisition 311.65 Mn 311.65 Mn - 144,789.00
6 Republic Digital Acquisition 310.50 Mn 309.63 Mn - 38,697.00
7 Siddhi Acquisition Corp (Cayman Islands) 288.97 Mn 288.97 Mn - -
8 K&F Growth Acquisition 283.42 Mn 283.42 Mn - -
9 Bold Eagle Acquisition 275.29 Mn 275.29 Mn - 30,671.00
10 Drugs Made In America Acquisition - - - 99,359.00

Historic Data

Download Data
DateValue
Dec 31, 2025 99,359.00
Sep 30, 2025 4,592.00
Dec 31, 2024 250,100.00